Skip to main content Back to Top
Advertisement

11/22/2017

Gentamicin Injection

Products Affected - Description

    • Gentamicin injection, Pfizer, 60 mg/50 mL, premixed bag, 24 count, NDC 00409-7879-13

Reason for the Shortage

    • Pfizer has discontinued all premixed bags.
    • Baxter did not provide a reason for the shortage.

Available Products

    • Gentamicin injection, Baxter, 100 mg/100 mL, premixed bag, 24 count, NDC 00338-0505-48
    • Gentamicin injection, Baxter, 100 mg/50 mL, premixed bag, 24 count, NDC 00338-0511-41
    • Gentamicin injection, Baxter, 120 mg/100 mL, premixed bag, 24 count, NDC 00338-0507-48
    • Gentamicin injection, Baxter, 60 mg/50 mL, premixed bag, 24 count, NDC 00338-0507-41
    • Gentamicin injection, Baxter, 80 mg/100 mL, premixed bag, 24 count, NDC 00338-0503-48
    • Gentamicin injection, Baxter, 80 mg/50 mL, premixed bag, 24 count, NDC 00338-0509-41
    • Gentamicin injection, Fresenius Kabi, 10 mg/mL, 2 mL vial, 25 count, NDC 63323-0173-02
    • Gentamicin injection, Fresenius Kabi, 40 mg/mL, 2 mL vial, 25 count, NDC 63323-0010-02
    • Gentamicin injection, Fresenius Kabi, 40 mg/mL, 20 mL vial, 25 count, NDC 63323-0010-20
    • Gentamicin injection, Pfizer, 40 mg/mL, 2 mL vial, 25 count, NDC 00409-1207-03

Estimated Resupply Dates

    • All marketed presentations are available.

Updated

Updated November 22, 2017 by Michelle Wheeler, PharmD, Drug Information Specialist. Created May 3, 2016 by Michelle Wheeler, PharmD, Drug Information Specialist. Copyright 2017, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.